EyePoint develops and commercializes sustained-release ocular therapeutics for serious retinal diseases. Its proprietary Durasert platform delivers drugs inside the eye over extended periods, aiming to reduce treatment burden versus frequent injections. Lead candidate DURAVYU (vorolanib in Durasert E) is in late-stage trials for wet age-related macular degeneration and diabetic macular edema. The company focuses on retina specialists and patients with chronic vision-threatening conditions.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 24.4 | — | -45.2 | — |
| Q2 2025 | 5.3 | — | -59.4 | — |
| Q3 2025 | 1 | — | -59.7 | — |
| Q4 2025 | 0.6 | — | -67.6 | — |
| Q1 2026 | 0.7 | -97.2% | -84.8 | — |
| Q2 2026 | 0.5 | -90.5% | -94.5 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Upstream Bio, Inc. (UPB), StablecoinX Inc. (USDE), Medallion Financial Corp. (MFIN), X4 Pharmaceuticals, Inc. (XFOR), RF Acquisition Corp II (RFAI), Coincheck Group N.V. (CNCK)